Scholarlink

<p>This research introduces a novel biosensor based on terahertz (THz) metamaterials, aimed at highly sensitive, label-free, and non-invasive detection of cancer. Utilizing the distinctive characteristics of THz metamaterials, the biosensor examines the variations in the refractive index of biological samples, offering an accurate instrument for early cancer diagnosis. The biosensor achieves impressive functionality with a sensitivity of 892&#xa0;GHz/RIU, a quality factor (Q) of 57.7, and a figure of merit of 18.98 RIU<sup>−1</sup>, and operates at a resonance frequency of 2.688 THz. With a groundbreaking design refined through the full finite element method, the sensor exhibits an absorption rate of 98% and can effectively identify subtle changes in the refractive index linked to several cancer types, such as Jurkat blood, HeLa cervical, PC-12 adrenal gland, MDA-MB-231 and MCF-7 breast cancers, along with basal skin cancer. This biosensor marks a significant leap forward in THz-based medical diagnostics, providing a compact, lab-on-chip compatible unit for swift, dependable, and early cancer detection at the cellular scale.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A multi-cancer metamaterial biosensor: refractive index-based identification of malignant cells

  • 期刊论文

  • 发表日期：

    2025年9月15日

查看全文
  • Nedjmeddine Mellak,
  • Bouchra Moulfi,
  • Tahar Aliouar

摘要

This research introduces a novel biosensor based on terahertz (THz) metamaterials, aimed at highly sensitive, label-free, and non-invasive detection of cancer. Utilizing the distinctive characteristics of THz metamaterials, the biosensor examines the variations in the refractive index of biological samples, offering an accurate instrument for early cancer diagnosis. The biosensor achieves impressive functionality with a sensitivity of 892 GHz/RIU, a quality factor (Q) of 57.7, and a figure of merit of 18.98 RIU−1, and operates at a resonance frequency of 2.688 THz. With a groundbreaking design refined through the full finite element method, the sensor exhibits an absorption rate of 98% and can effectively identify subtle changes in the refractive index linked to several cancer types, such as Jurkat blood, HeLa cervical, PC-12 adrenal gland, MDA-MB-231 and MCF-7 breast cancers, along with basal skin cancer. This biosensor marks a significant leap forward in THz-based medical diagnostics, providing a compact, lab-on-chip compatible unit for swift, dependable, and early cancer detection at the cellular scale.